Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1978 Dec;35(6):1017-25.

The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vitro

The capacity of microsomally-activated cyclophosphamide to induce immunosuppression in vitro

F L Shand. Immunology. 1978 Dec.

Abstract

Cyclophosphamide (CY) was activated in vitro with washed rat liver microsomes and cofactors. Pretreatment of mouse spleen cells in vitro with the activated drug abolished their capacity to give a primary antibody response to SRBC and levan on transfer to irradiated syngeneic recipients. However, responsiveness returned if challenge was delayed for 7 or more days after transfer. Part of this was shown to be of donor origin by an allotype marker. The treatment of normal spleen cells with activated CY in vitro also prevented B cells from regenerating their immunoglobulin receptors after capping with anti-immunoglobulin serum. The induction of suppression required contact between lymphocytes and activated CY for at least 30 min at 37 degrees and did not appear following incubation for 1 h at 0 degrees. Since the antibody response of drug-treated spleen cells to SRBC could not be restored with purified normal B or T cells, it is probable that B and T lymphocytes are both susceptible to suppression by activated CY in vitro. Similar pretreatment abrogated the graft-versus-host (GVH) reactivity of spleen cells as measured by survival and in a popliteal lymph node assay. B cell chimerism in F1 recipients of drug-treated parental spleen cells was demonstrated by the presence of congenic allotype markers. This suggests a possible approach for the attenuation of GVH disease which is associated with bone marrow transplantation in man.

PubMed Disclaimer

Similar articles

References

    1. Immunology. 1976 Dec;31(6):943-51 - PubMed
    1. Cancer Treat Rep. 1976 Apr;60(4):301-8 - PubMed
    1. Arzneimittelforschung. 1963 Dec;13:1021-31 - PubMed
    1. Nature. 1978 Jan 19;271(5642):255-7 - PubMed
    1. Eur J Immunol. 1977 Mar;7(3):180-5 - PubMed

Substances

LinkOut - more resources